Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
A 186.17 0.12% 0.23
JAZZ closed up 0.12 percent on Friday, June 11, 2021, on 1.7 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical JAZZ trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Older End-of-Day Signals for JAZZ ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Jazz Pharmaceuticals plc Description

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Drugs Pain Pharmaceutical Products Bone Imaging Monoclonal Antibody Lymphoma Prostate Cancer Antibiotic Symptoms Schizophrenia Chronic Pain Suspension Transplantation Acute Lymphoblastic Leukemia Movement Disorders Pharmacokinetics Narcolepsy Bones Host Disease Obsessive Compulsive Disorder Meningitis Oral Hygiene Organ Transplantation Pegylation Severe Chronic Pain Cataplexy Host Diseases Mucositis Organ Transplant Asparaginase Luvox Cr Oral Mucositis Panic Disorder

Is JAZZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 187.53
52 Week Low 103.46
Average Volume 643,705
200-Day Moving Average 157.95
50-Day Moving Average 171.54
20-Day Moving Average 177.98
10-Day Moving Average 178.40
Average True Range 4.05
ADX 31.2
+DI 32.78
-DI 10.77
Chandelier Exit (Long, 3 ATRs) 175.37
Chandelier Exit (Short, 3 ATRs) 183.25
Upper Bollinger Bands 184.92
Lower Bollinger Band 171.05
Percent B (%b) 1.09
BandWidth 7.80
MACD Line 2.87
MACD Signal Line 2.19
MACD Histogram 0.6869
Fundamentals Value
Market Cap 10.37 Billion
Num Shares 55.7 Million
EPS 3.16
Price-to-Earnings (P/E) Ratio 58.88
Price-to-Sales 3.55
Price-to-Book 2.36
PEG Ratio 4.98
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 190.27
Resistance 3 (R3) 190.26 188.90 189.58
Resistance 2 (R2) 188.90 187.85 188.90 189.35
Resistance 1 (R1) 187.53 187.21 186.85 187.54 189.13
Pivot Point 186.17 186.17 185.83 186.17 186.17
Support 1 (S1) 184.80 185.12 184.12 184.81 183.21
Support 2 (S2) 183.44 184.48 183.44 182.99
Support 3 (S3) 182.07 183.44 182.76
Support 4 (S4) 182.08